Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)’s share price was up 3.3% during mid-day trading on Thursday . The stock traded as high as $36.01 and last traded at $35.92, with a volume of 619,099 shares trading hands. The stock had previously closed at $34.78.

Several equities analysts have recently issued reports on PCRX shares. Wedbush reissued an “outperform” rating and set a $113.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, March 23rd. Mizuho started coverage on shares of Pacira Pharmaceuticals in a report on Tuesday, April 19th. They set a “buy” rating and a $79.00 price target for the company. Canaccord Genuity reissued a “buy” rating on shares of Pacira Pharmaceuticals in a report on Wednesday, April 20th. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 26th. Finally, TheStreet downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 2nd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. Pacira Pharmaceuticals presently has an average rating of “Hold” and an average target price of $78.15.

The company’s market cap is $1.37 billion. The stock has a 50 day moving average of $40.26 and a 200-day moving average of $52.91.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Monday, May 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.08. The company had revenue of $65.50 million for the quarter, compared to analyst estimates of $67.11 million. The business’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.27 earnings per share. Analysts expect that Pacira Pharmaceuticals Inc. will post $0.36 earnings per share for the current year.

In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 938 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $47.66, for a total transaction of $44,705.08. Following the completion of the transaction, the vice president now directly owns 5,945 shares in the company, valued at $283,338.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Kronenfeld sold 900 shares of the stock in a transaction on Monday, June 6th. The stock was sold at an average price of $46.95, for a total value of $42,255.00. Following the transaction, the director now owns 2,950 shares of the company’s stock, valued at $138,502.50. The disclosure for this sale can be found here.

Several hedge funds have made changes to their positions in PCRX. Russell Frank Co boosted its stake in shares of Pacira Pharmaceuticals by 934.0% in the fourth quarter. Russell Frank Co now owns 82,720 shares of the company’s stock valued at $6,371,000 after buying an additional 74,720 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Pacira Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 67,498 shares of the company’s stock valued at $5,183,000 after buying an additional 1,040 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Pacira Pharmaceuticals by 8.0% in the fourth quarter. Rhumbline Advisers now owns 42,471 shares of the company’s stock valued at $3,261,000 after buying an additional 3,160 shares during the last quarter. TD Asset Management Inc. boosted its stake in shares of Pacira Pharmaceuticals by 1.8% in the fourth quarter. TD Asset Management Inc. now owns 74,700 shares of the company’s stock valued at $5,736,000 after buying an additional 1,300 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Pacira Pharmaceuticals by 182.5% in the fourth quarter. California Public Employees Retirement System now owns 77,400 shares of the company’s stock valued at $5,944,000 after buying an additional 50,000 shares during the last quarter.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.